Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Report on combination therapy in advanced prostate cancer - ASCO GU 2022

Reporting from the ASCO Genitourinary Symposium 2022, Fred Saad provides an overview of practice changing studies with combination therapy in advanced prostate cancer. He features the improved rPFS demonstrated in PROpel and MAGNITUDE with a combination of PARPi with abiraterone or AAP in patients with mCRPC. He also discusses reduction in the risk of death by adding darolutamide to ADT + docetaxel in patients with mHSPC and other endpoints fovouring the triplet therapy.

Abstracts:

  • 11 - PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). - Fred Saad, USA
  • 12 - Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. - Kim Chi, USA
  • 13 - Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. - Matthew Smith, USA

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.